DS21360717 is a potent and orally active FER tyrosine kinase inhibitor, with an IC50 of 0.49 nM. Anti-cancer activity.

DS39201083 is a potent novel analgesic without mu opioid agonist activity. DS39201083 had a unique bicyclic skeleton and was a more potent analgesic than conolidine, as revealed in the acetic acid-induced writhing test and formalin test in ddY mice. The compound showed no agonist activity at the mu opioid receptor.

NV-5440 is a novel cell penetrant, potent and selective class I glucose transporters (GLUT1) inhibitor, selectively inhibiting mTORC1

NC-1 is a novel highly active allosteric inhibitor of protein tyrosine phosphatase, non-receptor type 22 (PTPN22) which is a lymphoid-specific tyrosine phosphatase (LYP).

BMS-986260 is a potent, selective, and orally bioavailable TGFβR1 inhibitor (IC50=1.6 nM). BMS-986260 demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.

Samidorphan, also known as ALKS-33 and RDC-0313, is an opioid modulator with μ-antagonist properties. It is under development by Alkermes for the treatment of major depressive disorder and possibly other psychiatric conditions.

Onvansertib fumarate is a A polo-like kinase 1 inhibitor, an antineoplastic

RK-582 is an orally efficacious spiroindolinone-based tankyrase inhibitor for the treatment of colon cancer. It exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered.

IACS-9439 is a potent, highly selective,and orally bioavailable CSF1R inhibitor. Treatment with IACS-9439 led to a dose-dependent reduction in macrophages,promoted macrophage polarization toward the M1 phenotype, and led to tumor growth inhibition in MC38 and PANC02 syngeneic tumor models.

MG-6267 is the first dual inhibitor of AChE and microRNA-15b biogenesis, protecting SH-SY5Y neuroblastoma cells from amyloid-beta (Aβ)-induced cytotoxicity

SSK1 is a senolytic prodrug, which was designed from gemcitabine, by chem. modifying gemcitabin to incorporate a site cleavable by SA-β-gal following delivery of the prodrug in vivo, to release the active parent drug gemcitabine. SSK1 can be used to reduce one or more symptoms associated with a Senescence-associated disease or disorder in a subject. SSK1 is specifically activated by β-gal and eliminates mouse and human senescent cells independently of senescence inducers and cell types. In aged mice, SSK1 effectively cleared senescent cells in different tissues, decreased the senescence- and age-associated gene signatures, attenuated low-grade local and systemic inflammation, and restored physical function.

ropsacitinib, also known as PF-06826647 and Tyk2-IN-8, is an orally administered, tyrosine kinase 2 (TYK2) inhibitor, that is in development with Pfizer for the treatment of plaque psoriasis and inflammatory bowel disease.

OP-5244 is a potent and orally bioavailable CD73 inhibitor.

Peptide5 is a connexin43 mimetic peptide. Peptide5 reduces swelling, astrogliosis, neuroinflammation and neuronal cell death following spinal cord injury ex vivo and in vivo. Peptide5 exhibits analgesic effects in models of neuropathic pain.

SPR519 is a potent dual inhibitor of PI3Kα and mTOR kinases with IC50 (PI3Kalpha) = 30 nM and IC50 (mTOR) = 10 nM. SPR519 exhibits an EC50 of low sub-micromolar range among various tested cancer cell lines such as A2780 (0.23 μM), PC3 (0.48 μM), and SKOV3 (0.50 μM).

Lenacapavir, also known as GS-6207, is a HIV-1 capsid inhibitor. Lenacapavir shows anti-HIV activity. Lenacapavir displays a mean EC50 of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs). Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapavir regardless of treatment history.

C5-RIBOTAC is a RIBOTAC degrader, targeting the SARS-CoV-2 RNA genome

CG416 is a tropomyosin receptor kinase (TRK) degrader that targets the intracellular kinase domain of TRK. CG416 reduced levels of the tropomyosin 3 (TPM3)-TRKA fusion protein in KM12 colorectal carcinoma cells and inhibited downstream PLCγ1 signaling at sub-nanomolar concentrations. CG416 also degraded human wild-type TRKA.

BI 730357 is a RORγ Antagonist for the treatment of autoimmune diseases.

PIPE-359 is a brain-penetrant and selective antagonist of the muscarinic acetylcholine receptor subtype 1.

KGN-00429 is a novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo. This product has no formal name. For the convenience of scientific communication, we named it by combining its InChi Key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature (https://www.medkoo.com/page/naming).

DS79932728 is a Potent, Orally Available G9a/GLP Inhibitor for Treating β‑Thalassemia and Sickle Cell Disease.

MI-09 is a SARS-CoV-2 Protease inhibitor (IC50 = 15.2 nM). In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment with MI-09 significantly reduced lung viral loads and lung lesions.

SR-1114 is a first-in-class ENL PROTAC.

SMU-C80 is a TLR2 agonist (EC50 = 31.02 ± 1.01 nM). SMU-C80, through TLR1/2, recruits the adaptor protein MyD88 and triggers the NF-κB pathway to release cytokines such as TNF-α and IL-1β from human, but not murine, cells. To the best of our knowledge, it is the first species-specific TLR1/2 agonist reported until now. Moreover, SMU-C80 increased the percentage of T, B, and NK cells ex vivo and activated the immune cells, which suppressed cancer cell growth in vitro.

Icenticaftor, also known as QBW251 is a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

GSK743 is a Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitor.

SKLB-C2807 is an AR-DBD binder.

LC28 is a novel inhibitor of STAT3 signaling, suppressing survival of cisplatin-resistant ovarian cancer cells.

MMPP is a novel potent inhibitor of pro-inflammatory responses by inhibiting in vitro STAT3 activation and its downstream signalling in murine macrophages and human synoviocytes from patients with RA.

VPC-70063 is a Myc-Max inhibitor. VPC-70067 is a close analog of the previously identified Myc inhibitor 10058-F4. VPC-70063, of a chemically different scaffold, was the best performer in a panel of in vitro assays, and the forerunner for future hit-to-lead optimization efforts.

IACS-9779 is a Potent IDO1 Inhibitor Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme. IACS-9779 with a predicted human efficacious once daily dose below 1 mg/kg to sustain >90% inhibition of IDO1 displayed an acceptable safety margin in rodent toxicology and dog cardiovascular studies to support advancement into preclinical safety evaluation for human development.

Muscarine ((+)-Muscarine) is a toxin that can stimulate the parasympathetic nervous system. Muscarine is an agonist of muscarinic acetylcholine receptor (mAChR).

Leniolisib (CDZ173) phosphate is a potent and selective PI3Kδ inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment.

Formamide (Methanamide; Formimidic acid) is a clear liquid amide derived from formic acid. It allows for the denaturation and renaturation of nucleic acids at room temperature. Formamide-induced DNA denaturation when combined with detection of denatured DNA with a monoclonal antibody (MAb) makes it possible to specifically identify the apoptotic cells.

MTK458 (MTK-458) is a potent, selective and brain penetrant PINK1 activator, MTK-458 promotes the first step in mitophagy. MTK458 selectively activates PINK1 by stimulating dimerization and stabilization of the PINK1/TOM complex. MTK458 binds to PINK1 and stabilizes an active heterocomplex, thereby increasing mitophagy. MTK458 reduces the PINK1 substrate pS65-Ubiquitin (pUb) in primary neurons and in vivo. MTK458 drives clearance of pathologic α-synuclein in vitro and in vivo, decreases pS129 α-synuclein aggregates and normalized both brain and corresponding plasma pUb levels in both cellular and animal models of α-synuclein aggregation (PD-like pathology).

UNC7145 is a negative control for UNC6934 (GLXC-22088).

BAY-297 is a potent and selective PIP4K2A inhibitor. BAY-297 can serve as valuable chemical probes to study PIP4K2A signaling and its involvement in pathophysiological conditions such as cancer.

BT8009 is a Nectin-4 targeting toxin conjugate with a Kd value of 2.5 nmol/L for human Nectin-4 (hNectin-4) extra-cellular domain (ECD). BT8009 consists of a Nectin-4-binding bicyclic peptide, a cleavable linker system and monomethylauristatin E (MMAE). BT8009 can be used for the research of advanced and metastatic urothelial cancer.

Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD).

NX-2127 is a potent, selective, and orally bioavailable BTK degrader with Kd of 18 nM (for WT BTK), 45 nM (BTK C481S), 18 nM (BTK T474I), 44 nM (BTK M437R), 97 nM (BTK V416L), and 88 nM (BTK L528W), respectively. NX-2127 efficiently engages the intracellular ubiquitin-proteasome system to simultaneously bind both BTK and the CRBN E3 ubiquitin ligase complex, inducing polyubiquitination and proteasome-dependent degradation of BTK, IKZF1, and IKZF3.

MK-0616 is a potent, oral macrocyclic peptide inhibitor of PCSK9 that is not only able to reduce LDL-cholesterol, non-HDL-cholesterol, and apoB, but can also lower Lp(a).

BIOTIN-11-DCTP is a fluorescent dye for DNA labeling.

306-N16B is a lipidnanoparticle, and allows systemic codelivery of Cas9 mRNA and sgRNA. 306-N16B can transport mRNA to the pulmonaryendothelial cell. 306-N16B can be used for research of genome editing-based therapies. Based on the same lipid libraries with 306-O12B, the researchers also found that N-series ionizable lipids were able to selectively deliver mRNA to the lungs of mice. Compared with the liver-targeted O-series ionizable lipids which contained ester bond in lipid tail found in previous work, such as 306-O12B, the N-series ionizable lipids with the lipid tail containing amide bond prefer to deliver mRNA to the lung. As a N-series ionizable lipid, the chemical structure of the 306-N16B is shown in Figure 4a,b. The difference of organ targeting may be due to their adsorption of different protein coronas during blood circulation caused by their different structures mentioned earlier.It has shown that the second major protein of the protein corona adsorbed by liver-targeting 306-O12B iLNPs was apolipoprotein E (ApoE), while the three dominant proteins in the protein corona adsorbed by lung-targeting 306-N16B iLNPs were serum albumin, fibrinogen beta chain, and fibrinogen gamma chain. However, the 306-N16B iLNPs showed less organ selectivity when systematically codelivered Cas9 mRNA and sgRNA in vivo, which could simultaneously activate tdTomato expression in the liver and lung of Ai14 mice, whereas single mRNA delivery could almost exclusively deliver mRNA to the lungs. This surprising phenomenon requires further investigation. Both the change of iLNPs charge and the change of lipids functional group can influence the distribution of iLNPs in vivo due to the altering of protein corona composition. Therefore, it is possible to control the organ targeting of iLNPs by controlling the composition of the outer protein corona of iLNPs.

AA-T3A-C12 is an anisamide ligand-tethered lipidoid (AA-lipidoid) with high potency and selectivity to deliver RNA payloads to activated fibroblasts. HSP47 siRNA (siHSP47)-loaded AA-T3A-C12 LNP achieves ~65% knockdown and dramatically reduces liver fibrosis, which significantly outperforms the benchmark DLin-MC3-DMA (MC3) LNP.

ALC-0315 analogue-2 is an analogue of ALC-0315. ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine.

Lipid 1 is an ionizable amino lipid used for the generation of Lipid nanoparticles (LNPs).

LNP Lipid-1 (Method B) is a lipid compound. LNP Lipid-1 is involved in the synthesis of lipid nanoparticles compositions. LNP Lipid-1 has potential applications in the transport of biologically active substances such as small molecule drugs, proteins, and nucleic acids.

Lipid 6 is an ionizable amino lipid used for the generation of Lipid nanoparticles .

A2-Iso5-4DC19 is a lipidoid compound. A2-Iso5-4DC19 is an effective carrier for the delivery of an agent such as a polynucleotide to a cell.

Lipid 15 is an ionizable amino lipid used for the generation of Lipid nanoparticles .

LNP Lipid-5 (Compound Lipid 2) is an ionizable lipid (amino lipid). LNP Lipid-5 can be used to prepare lipid nanoparticles .

244cis is a piperazine-based biodegradable ionizable lipid for LNP formulation. 244cis LNP has great potential for the treatment of chronic diseases in the lungs with improved potency and safety due to its low immunogenicity.

PSMA-1007 is a novel Glu-Ureido-type prostate-specific membrane antigen (PSMA) inhibitor.

DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

Pentixafor is a ligand to make gallium Ga 68-pentixafor, a radioconjugate composed of a synthetic, cyclic pentapeptide analog of stromal-cell derived factor-1 (SDF-1 or CXCL12), which is a ligand for chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), that is radiolabeled, via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA), with the radioisotope gallium Ga 68 (Ga68; 68Ga), with potential use for imaging CXCR4-expressing cells upon positron emission tomography (PET)/computed tomography (CT). Upon administration of 68Ga-pentixafor, the pentixafor moiety targets and binds to CXCR4-expressing cancer cells. Upon PET/CT, CXCR4-expressing cancer cells can be visualized and the expression status of the receptor can be assessed. CXCR4, a marker of poorly differentiated cells, is overexpressed on various cancer cells, and plays a key role in tumor growth, progression, invasiveness and metastasi

R6 is a new ionizable lipid driven from AI-Guided Ionizable Lipid Engineering (AGILE) platform for mRNA delivery. R6 LNPs exhibits a 5-fold increase in transfection potency in RAW 264.7 and shows its potential to be utilized for the development of non-viral mRNA delivery vectors for immune cells.

H9 is a new ionizable lipid driven from AI-Guided Ionizable Lipid Engineering (AGILE) platform for mRNA delivery. H9 LNPs shows superior mRNA transfection potency compared to LNPs containing (D-Lin-MC3-DMA).

UAMC1110-NH2 (NH2-UAMC1110)is a derivative of UAMC1110 with a aminobutoxy group, which is useful to synthesie UAMC1110 conjugate. UAMC-1110, also known as SP-13786, is a novel potent and selective inhibitor of fibroblast activation protein (fap), displaying low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (dpps) dppiv, dpp9, dppii, and prolyl oligopeptidase (prep).

[18F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of biochemical recurrence, which significantly affects patient management. Herein, we established and optimized a one-step radiolabeling protocol to separate and purify [18F]PSMA-1007 with a CFN-MPS200 synthesizer for clinical application.

Fmoc-Cit-PABA is a peptide linker useful for drug conjugate synthesis or ADC synthesis.

SU-5616 is a biochemical reagent. SU 5616 potentially modulates tyrosine kinase signal transduction, and regulates abnormal cell proliferation.

KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC50 value of 88 nM. KWCN-41, specifically inhibiting cell necroptosis but not apoptosis, protects cell survival by blocking the necroptotic pathway, which inhibits the phosphorylation of essential proteins of the necroptosis. It also prevented the development of inflammation and reduced the level of inflammatory factors in mice. KWCN-41 is expected to be a lead compound for further studies in inflammatory diseases.

TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity.

ZM-226600 is a potent Kir6 (KATP) channel opener (EC50 = 0.5 μM), devoid of antiandrogen properties. ZM226600 is more active than oxybutynin in reducing bladder overactivity, and it is devoid of vascular side effects observed with pinacidil. Its short duration of action (about 1 h) is probably the main problem to solve, in order to consider this compound a valid alternative to antimuscarinics in the therapy of bladder overactivity.

A-674563 is a potent and selective Akt1 inhibitor with Ki of 11 nM. A-674563 suppressed the activation of the NLRP3 inflammasome in cardiomyocytes following β-adrenoceptor activation, suggesting that AKT1 is a critical regulator molecule upstream of the NLRP3 inflammasome. A-674563 suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206

C12-TLRa is an adjuvant lipidoid. C12-TLRa substitution can enhance the immunogenicity of clinically relevant SARS-CoV-2 mRNA-LNP vaccines, which holds translational potential.

Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors.

Lirafugratinib (RLY-4008) is an orally active and selective inhibitor of FGFR2.

Z0933M is a potent S phase kinase-associated protein 1 (Skp1) inhibitor with Kd of 54 nM, potently inhibits Skp1-F-box protein-protein interactions with Ki value of 231 nM in FP-based in vitro competition assays.

CWI1-2 hydrochloride is an inhibitor of IGF2BP2 that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.

MEHP (Phthalic acid mono-2-ethylexyl ester) is a competitive inhibitor of CYP2C9 with IC50 of 6.37 μM.

TP-1454 is an activator of PKM2 with AC50 of 10 Nm in biochemical assays.TP-1454 modulates tumor-immune responses by destabilizing T-regulatory cells.

DOG-IM4 is an ionizable cationic lipid (apparent pKa = 5.6) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA.1 Immunization with LNPs containing DOG-IM4 and encapsulating mRNA encoding influenza A hemagglutinin (HA) increases HA-inhibiting antibody titers (HI titers) in mice and cynomolgus macaques.

ALC-0315 analgous-3 is an butanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315.

BP Lipid 101 is an amino ionizable lipid analogous to SM-102. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C6 position relative to the amine nitrogen. The primary lipid tail has 7 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 102 is an ionizable lipid used to prepare lipid nanoparitlcels (LNPs). The lipid has ethanolamine as a lipid head group which enhances the mRNA encapsulation and provides exceptional physiochemical properties. Both esters of the lipid are at the C6 position relative to the amine. The lipid can be used for mRNA delivery. Reagent grade, for research purpose.

BP Lipid 103 is an amine ionizable lipid analogous to SM-102. The ethanolamine head improves encapsulation of mRNA. The lipid has both esters at C6 position relative to the amine nitrogen. Ester linkages in the lipid tails are introduced into the structure to improve tissue clearance. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research only.

BP Lipid 104 is an ionizable lipid with ethanolamine head to enhance mRNA encapsulation. Ester linkages at C7 position relative to amine are introduced into the structure to improve tissue clearance. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 105 is an ethanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. The ester bonds, located at C7 relative to amine nitrogen, improve tissue clearance. Reagent grade, for research purpose.

BP Lipid 106 is an amino ionizable lipid with ester bonds located at C7 relative to nitrogen. The ethanolamine head can effectively enhance mRNA encapsulation while ester bonds improve tissue clearance. The primary lipid tail contains 11 carbons. The ionizable lipid can be used for mRNA delivery due to its excellent physiochemical properties. Reagent grade, for research purpose.

BP Lipid 107 is an ionizable amino lipid with both ester linkages located at C8 position relative to nitrogen amine. There is 7 carbons chain on the primary ester lipid tail. The secondary ester is introduced to improve protein expression. Reagent grade, for research purpose.

MS78 is the first p53Y220C AceTAC which recruits histone acetyltransferase p300/CBP to acetylate the p53Y220C mutant with little toxicity in cancer cells with wild-type p53.

BP Lipid 109 is an amine lipid which has long (11 carbons) lipid tail on the primary ester. Both esters are located at C7 position and the head contains ethanolamine which can efficiently encapsulate mRNA. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose.

BP Lipid 110 is an ionizable amino lipid with ester likages located at C6 and C7 position relative to amine. The ethanolamine moiety can enhance encapsulation of mRNA. The lipid has a relatively short primary ester lipid tail (7C). Reagent grade, for research purpose.

BP Lipid 111 is an ionizable amine lipid with ethanolamine head for efficient mRNA encapsulation. The lipid has two ester linkages at C6 and C7 position. The C6 ester has a 9-carbons lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 112 is an amine lipid with two ester linkages at C6 and C7 position. The C6 ester has a long 11 carbons lipid tail. The head of lipid is ethanolamine which can effectively encapsulate mRNA used in gene therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 113 is an ionizable lipid analogous to SM-102. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C6 and C8 position relative to the amine nitrogen. The primary ester at C6 position has a 7-carbons lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 114 is an ethanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. The ester bonds are located at C6 and C8 position relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose.

BP Lipid 116 is an ionizable amine lipid with ethanolamine head which can efficiently encapsulate mRNA. Ester linkages are incorporated, at C7 adn C6 position relative to amine, in the structure to increase tissue clearance of the lipid in the liver. The primary ester has a 7-carbons lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 117 is an ethanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. The ester bonds, located at C7 and C6 relative to amine nitrogen, are introduced in the structure to improve tissue clearance. Reagent grade, for research purpose.

BP Lipid 118 is an amino ionizable lipid with ester bonds located at C7 and C6 poisiton relative to nitrogen. The ethanolamine head can effectively improve mRNA encapsulation while introduction of ester bonds improve tissue clearance. The primary ester contains a long 11 carbons tail. The ionizable lipid can be used for mRNA delivery due to its excellent physiochemical properties. Reagent grade, for research purpose.

BP Lipid 119 is an ionizable amino lipid with both ester linkages located at C7 and C8 position relative to nitrogen amine. There is 7 carbons chain on the primary ester lipid tail. The ethanolamine head help encapsulation of mRNA while the introduction of secondary ester can improve protein expression. Reagent grade, for research purpose.

BP Lipid 120 is an amine lipid with two ester linkages at C7 and C8 position relative to the amine. The C7 ester has a medium length (9 carbons) lipid tail. The head of lipid is ethanolamine which can effectively encapsulate mRNA used in gene therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

Lipid 121 is an amino lipid which has a long (11 carbons) lipid tail on the primary ester located at C7 relative to nitrogen amine. The head contains ethanolamine which can efficiently encapsulate mRNA. The secondary ester is introduced, on the ester located at C8 position relative to amine, to improve protein expression in the liver. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose.

AZD4747 is a highly potent and selective inhibitor of KRASG12C with IC50 of 15 nM. AZD4747 also shows an anticipated low clearance and high oral bioavailability profile in humans.

BP Lipid 122 is an ionizable amine lipid with ethanolamine head which can efficiently encapsulate mRNA. Ester linkages are incorporated in the structure at C8 adn C6 position relative to amine. These introduction of ester bonds can increase tissue clearance of the lipid in the liver. The primary ester at C8 poisition has a 7-carbons lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis.

CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.

BP Lipid 123 is an ionizable amino lipid with both ester linkages located at C8 and C6 position relative to nitrogen amine. There is 9 carbons chain on the primary ester lipid tail. The secondary ester is introduced to improve protein expression. The lipid head contains ethanolamine which can effectively encapsulate mRNA for gene therapies. Reagent grade, for research purpose.

BP Lipid 124 is an ethanolamine ionizable lipid with 11 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. The ester bonds are located at C8 and C6 position relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose.

BP Lipid 125 is an ionizable lipid analogous to SM-102. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C8 and C7 position relative to the amine nitrogen. The primary lipid tail has 7 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 126 is an amino ionizable lipid with ester bonds located at C8 and C7 position relative to nitrogen. The ester linkages are introduced to improve tissue clearance. The ethanolamine head can effectively enhance mRNA encapsulation. The primary ester at C8 position contains 9 carbons lipid tail. The ionizable lipid can be used for mRNA delivery due to its excellent physiochemical properties. Reagent grade, for research purpose.

BP Lipid 127 is an ethanolamine ionizable lipid with 11 carbons lipid tail attached on the primary-ester located at C8 position relative to amine. The second ester bond is located at C7 position relative to the amine nitrogen and has secondary ester lipid tail which can improve protein expression. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose.

BP Lipid 210 is an ionizable lipid used to prepare lipid nanoparitlcels (LNPs). The lipid has ethanolamine as a lipid head group which enhances the mRNA encapsulation and provides exceptional physiochemical properties. The esters of the lipid are at the C10 and C8 position relative to the amine. The primary ester has a relatively long lipid tail (9 carbons). The lipid can be used for mRNA delivery. Reagent grade, for research purpose.

BP Lipid 209 is an amine lipid which has a 9-carbons lipid tail on the primary ester. Both esters are located at C8 and C10 position relative to the amine nitrogen. The head contains ethanolamine which can efficiently encapsulate mRNA. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose.

BP Lipid 213 is an amino lipid with ester bonds located at C10 and C8 position relative to nitrogen amine. The ethanolamine head can effectively enhance mRNA encapsulation while ester bonds improve tissue clearance. The primary lipid tail contains 11 carbons. The ionizable lipid can be used for mRNA delivery due to its excellent physiochemical properties. Reagent grade, for research purpose.

BP Lipid 212 is an amino ionizable lipid analogous to BP-25499. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C8 and C10 position relative to the amine nitrogen. The primary ester has lipid a long 11-carbons tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 214 is an inonizable amine lipid with two ester linkages at C10 position relative to amine. The primary C10 ester has a long 11 carbons lipid tail. The head of lipid is ethanolamine which can effectively encapsulate mRNA used in gene therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 128 is an ionizable lipid analogous to SM-102. The propanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C6 position relative to the amine nitrogen. The primary lipid tail has 7 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 129 is an amine ionizable lipid used to prepare lipid nanoparitlcels (LNPs). The lipid has propanolamine as a lipid head group which enhances the mRNA encapsulation and provides exceptional physiochemical properties. Both esters of the lipid are at the C6 position relative to the amine. The lipid can be used for mRNA delivery. Reagent grade, for research purpose.

BP Lipid 130 is an ionizable amine lipid analogous to SM-102. The propanolamine head improves encapsulation of mRNA. The lipid has both esters at C6 position relative to the amine nitrogen. Ester linkages in the lipid tails are introduced into the structure to improve tissue clearance. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.BP Lipid 130 is an ionizable amine lipid analogous to SM-102. The propanolamine head improves encapsulation of mRNA. The lipid has both esters at C6 position relative to the amine nitrogen. Ester linkages in the lipid tails are introduced into the structure to improve tissue clearance. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 131 is an amino ionizable amine lipid with propanolamine head to enhance mRNA encapsulation. Ester linkages at C7 position relative to amine are introduced into the structure to improve tissue clearance. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 132 is a propanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The propanolamine head helps with mRNA encapsulation. The ester bonds, located at C7 relative to amine nitrogen, improve tissue clearance. Reagent grade, for research purpose.

C12-113 is a novel polyamine-derived lipidoid for gene delivery.

BP Lipid 133 is an amino ionizable lipid with ester bonds located at C7 relative to nitrogen. The propanolamine head can effectively enhance mRNA encapsulation while ester bonds improve tissue clearance. The primary lipid tail contains 11 carbons. The ionizable lipid can be used for mRNA delivery due to its excellent physiochemical properties. Reagent grade, for research purpose.

BP Lipid 134 is an ionizable amino lipid with both ester linkages located at C8 position relative to nitrogen amine. There is 7 carbons chain on the primary ester lipid tail. The secondary ester is introduced to improve protein expression. Reagent grade, for research purpose.

BP Lipid 135 is an amino ionizable lipid with propanolamine lipid head which can improve mRNA encapsulation. The ester bonds are located at C8 position relative to nitrogen amine. There is 9 carbons chain on the primary ester lipid tail. The lipid can be used for preparation mRNA vesicle in gene therapy. Reagent grade, for research purpose.

BP Lipid 136 is an amino lipid which has long (11 carbons) lipid tail on the primary ester. Both esters are located at C7 position and the head contains propanolamine which can efficiently encapsulate mRNA. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose.

BP Lipid 137 is an ionizable amino lipid with ester likages located at C6 and C7 position relative to amine. The propanolamine moiety can enhance encapsulation of mRNA. The lipid has a relatively short primary ester lipid tail (7C). Reagent grade, for research purpose.

BP Lipid 138 is an ionizable amine lipid with propanolamine head for efficient mRNA encapsulation. The lipid has two ester linkages at C6 and C7 position. The C6 ester has a 9 carbons lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 139 is an amine lipid with two ester linkages at C6 and C7 position. The C6 ester has a long 11 carbons lipid tail. The head of lipid is propanolamine which can effectively encapsulate mRNA used in gene therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 140 is an ionizable lipid analogous to SM-102. The propanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C6 and C8 position relative to the amine nitrogen. The primary ester at C6 position has a 7-carbons lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 141 is a propanolamine ionizable lipid with ester bonds located at C6 and C8 relative to amine nitrogen. The ester linkages can improve tissue clearance. The ester at C6 position has a 9-carbon lipid tail. The propanolamine head helps with mRNA encapsulation. Reagent grade, for research purpose.

BP Lipid 142 is an ionizable amine lipid analogous to SM-102. The propanolamine head improves encapsulation of mRNA. The lipid has both esters at C6 and C8 position relative to the amine nitrogen. Ester linkages in the lipid tails are introduced into the structure to improve tissue clearance. The primary ester located at C6 is attached with a long (11-carbon) lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 143 is an ionizable amino lipid with propanolamine head which can efficiently encapsulate mRNA. Ester linkages are incorporated, at C7 adn C6 position relative to amine, in the structure to increase tissue clearance of the lipid in the liver. The primary ester has a 7-carbons lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 144 is a propanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The propanolamine head helps with mRNA encapsulation. The ester bonds, located at C7 and C6 relative to amine nitrogen, are introduced in the structure to improve tissue clearance. Reagent grade, for research purpose.

BP Lipid 145 is an amino ionizable lipid with ester bonds located at C7 and C6 poisiton relative to nitrogen. The propanolamine head can effectively improve mRNA encapsulation while introduction of ester bonds improve tissue clearance. The primary ester contains a long 11 carbons tail. The ionizable lipid can be used for mRNA delivery due to its excellent physiochemical properties. Reagent grade, for research purpose.

BP Lipid 146 is an ionizable amino lipid with both ester linkages located at C7 and C8 position relative to nitrogen amine. There is 7 carbons chain on the primary ester lipid tail. The propanolamine head help encapsulation of mRNA while the introduction of secondary ester can improve protein expression. Reagent grade, for research purpose.

BP Lipid 147 is an amine lipid with two ester linkages at C7 and C8 position relative to the amine. The C7 ester has a medium length (9 carbons) lipid tail. The head of lipid is propanolamine which can effectively encapsulate mRNA used in gene therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 148 is an amino lipid which has a long (11 carbons) lipid tail on the primary ester located at C7 relative to nitrogen amine. The head contains propanolamine which can efficiently encapsulate mRNA. The secondary ester is introduced, on the ester located at C8 position relative to amine, to improve protein expression in the liver. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose.

BP Lipid 149 is an ionizable amine lipid with propanolamine head which can efficiently encapsulate mRNA. Ester linkages are incorporated in the structure at C8 adn C6 position relative to amine. These introduction of ester bonds can increase tissue clearance of the lipid in the liver. The primary ester at C8 poisition has a 7-carbons lipid tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 150 is an ionizable amino lipid with both ester linkages located at C8 and C6 position relative to nitrogen amine. There is 9 carbons chain on the primary ester lipid tail. The secondary ester is introduced to improve protein expression. The lipid head contains propanolamine which can effectively encapsulate mRNA for gene therapies. Reagent grade, for research purpose.

BP Lipid 151 is a propanolamine ionizable lipid with 11 carbon of primary-ester lipid tail. The propanolamine head helps with mRNA encapsulation. The ester bonds are located at C8 and C6 position relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose.

BP Lipid 152 is an ionizable lipid analogous to SM-102. The propanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C8 and C7 position relative to the amine nitrogen. The primary lipid tail has 7 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

BP Lipid 153 is an amino ionizable lipid with ester bonds located at C8 and C7 position relative to nitrogen. The ester linkages are introduced to improve tissue clearance. The propanolamine head can effectively enhance mRNA encapsulation. The primary ester at C8 position contains 9 carbons lipid tail. The ionizable lipid can be used for mRNA delivery due to its excellent physiochemical properties. Reagent grade, for research purpose.

BP Lipid 154 is a propanolamine ionizable lipid with 11 carbons lipid tail attached on the primary-ester located at C8 position relative to amine. The second ester bond is located at C7 position relative to the amine nitrogen and has secondary ester lipid tail which can improve protein expression. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose.

BP Lipid 226 is an amino ionizable lipid analogous to ALC-0315. The ethanolamine lipid head enhances encapsulation of mRNA. The lipid has identical ester bonds located adjacent to C6 relative to the amine nitrogen. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 216 is an amine lipid which has both ester bonds located adjacent to C7 relative to the nitogen amine. The head contains ethanolamine which can efficiently encapsulate mRNA. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 218 is an ionizable amine lipid with two identical ester tails adjacent to C6 position relative to amine. The head of lipid is propanolamine which can effectively encapsulate mRNA used in gene therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 219 is an amine ionizable lipid analogous to BP-25498 (ALC-0315). The propanolamine lipid head enhances encapsulation of mRNA. The lipid has identical ester bonds located adjacent to C7 relative to the amine nitrogen. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 220 is an amino lipid which has both ester bonds located adjacent to C8 relative to the nitogen amine. The head contains propanolamine which can efficiently encapsulate mRNA. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 221 is an ionizable amino lipid which has both ester bonds located adjacent to C7 relative to the nitogen amine. This lipid is an analogous to BP-25498/ALC-0315. The head contains butanolamine which can efficiently encapsulate mRNA. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 223 is an pentanolamine lipid with both ester bonds located adjacent to C6 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 224 is an amino ionizable lipid analogous to BP-25498/ALC-0315. The pentanolamine lipid head enhances encapsulation of mRNA. The lipid has identical ester bonds located adjacent to C7 relative to the amine nitrogen. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 225 is an ionizable amine lipid with two identical ester tails adjacent to C8 position relative to amine. The head of lipid is pentanolamine which can effectively encapsulate mRNA used in gene therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 400 is a cationic lipid-like compound containing a polar alcohol head group, two amides, four hydrophobic tails, and a tertiary amine linker. The lipoid can be formulated into a lipid nanoparticle (LNP) to deliver anionic substrates in vitro and in vivo. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 700 is a cationic lipid-like PEG compound containing a polar alcohol head group, four hydrophobic tails bound by esters, and a tertiary amine linker. The hydrophilic PEG linker increases the water solubility of the compound in aqueous media. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

Bis(N-2-ethoxyethyl 2-hexyldecanoate)amine is a cationic lipid-like PEG compound containing a polar alcohol head group, four hydrophobic tails bound by esters, and a tertiary amine linker. The hydrophilic PEG linker increases the water solubility of the compound in aqueous media. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 800 is a cationic lipid-like PEG compound containing a polar alcohol head group, four hydrophobic tails bound by esters, and a tertiary amine linker. The hydrophilic PEG linker increases the water solubility of the compound in aqueous media. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 227 is an amino ionizable lipid. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C5 position relative to the amine nitrogen. The primary lipid tail has 8 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 1000 is an amino ionizable lipid. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C6 position relative to the amine nitrogen. The primary lipid tail has 8 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 229 is an amino ionizable lipid with an ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C8 position relative to the amine nitrogen. The lipid tails have 6 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

An analog of SM-102. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C7 position relative to the amine nitrogen. The primary lipid tail has 8 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle.

BP Lipid 306 is an amino ionizable lipid with an butanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C8 position relative to the amine nitrogen. The lipid tails have 8 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose.

AkaLumine hydrochloride is a luciferin analogue, with a Km of 2.06 μM for recombinant Fluc protein.

LNP Lipid-2 is a lipid product can be used to deliver agents.

SM-102 Analog 2(Compound 8-8) is a lipid compound. SM-102 Analog 2(Compound 8-8) is involved in the synthesis of lipid nanoparticles compositions. SM-102 Analog 2(Compound 8-8) has potential applications in the transportation of biologically active substances.

LNP Lipid-6 (Compound Lipid 5) is an ionizable lipid (amino lipid). LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP).

1-Methoxy PES is an electron mediator which has higher stability of solutions than 1-Methoxy PMS(M003). The stability in neutral to alkali conditions has been extremely improved with 1-Methoxy PES. 1-Methoxy PES is a stable small-molecular compound and it has an equal or higher thermal stability than diaphorase. The 1-Methoxy PES solution can be stored long term.

Lipidoid XMaN6 is an ionizable lipid with universality was screened out from the adamantyl-based ionizable lipid series, which could functionally deliver highly diverse types of nucleic acids. Among them, the XMaN6 iLNPs were the best-delivering vectors. XMaN6 was used to deliver mRNA, siRNA, pDNA, and cyclic dinucleotide into different cells, including human primary hepatocytes, HEK293T, Huh7, HepG2, and U2OS cell, with nontoxicity after a single dose.The non-toxic XMaN6 lipidoid is highly versatile in entrapment and delivery of siRNA, mRNA, plasmid DNA, and a cyclic dinucleotide. XMaN6-based LNPs efficiently deliver: 1) siRNA into human primary hepatocytes and cell lines that are hard-to-transfect, 2) mRNA into mouse liver, 3) plasmid DNA, 4) 2′,3′-cGAMP into cells and activated the cGAS-STING pathway three orders of magnitude more efficiently than 2′,3′-cGAMP alone. To our knowledge, such universality in delivering different NA types has not been previously described and can accelerate translation of LNPs into the clinic.

ssPalmE-P4C2 contained vitamin E (α-tocopherol) as a hydrophobic scaffold instead of oleic acid. ssPalmE-P4C2 was reported to have the ability to deliver siRNA to the liver. LNPssPalmE-P4C2 and LNPssPalmO-P4C2 showed a comparable knockdown efficiency (15.4 ± 8.7% and 19.2 ± 4.4%, respectively).

TCIP1 is the most potent transcriptional/epigenetic CIP (chemical inducers of proximity) and specifically activates BCL6 target genes. TCIP1 kills diffuse large B cell lymphoma cell lines, including chemotherapy-resistant, TP53-mutant lines and exhibits cell-specific and tissue-specific effects. TCIP1 successfully killed large B cell lymphoma cell lines, including chemotherapy-resistant TP53-mutant lines and exhibited cell-specific and tissue-specific effects. The activation of apoptosis to cell death took place in just 72 hours.BCL6 is critical to the lymphatic system, and mice engineered without the BCL6 gene die of complex inflammatory reactions. BRD4 is heavily involved in genome function and stability across many processes. Concerns regarding utilizing these important gene expressions and how they might affect off-target healthy tissues were addressed in the study.TCIP1 acts in a context-specific manner requiring the expression of BRD4 and BCL6 to both be present in order to bind them and operate at a concentration that would occupy only a tiny fraction of the total BCL6 molecules.TCIP1 induced dramatic transcriptomic changes in the spleen, notably with an upregulation of the FOXO3 gene, which mirrored activity in the targeted cancer cells. Despite the significant transcriptomic changes in the spleen, TCIP1 was well tolerated without adverse effects, with no significant differences in mouse body weight and no noticeable abnormalities such as inflammatory infiltrates or apoptotic cells. BCL6-BRD4 TCIP1 (TCIP1) is a potent BCL6-BRD4 transcriptional/epigenetic chemical inducer of proximity (TCIP) by covalently linking BCL6 binder BI-3812 to BRD4 ligand JQ1, selectively kills DLBCL cells with EC50 of 1.3 nM against KARPAS422 cell. TCIP1 rapidly and robustly killed other DLBCL lines with high levels of BCL6, but JQ1 and BI3812 separately or together shows100–1,000-fold less-effective cell killing. TCIP1 is 200–10,000-fold more potent in killing DLBCL cells than the degradation of BRD4 by dBET1 and/or degradation of BCL6 by BI3802. TCIP1 induces a stable, cooperative protein-protein interaction between bromodomain 1 (BD1) of BRD4 and the BTB domain of BCL6. TCIP1 shows affinity for intracellular ternary complex of BRD4 with Kd of 340 nM in TR-FRET assays. TCIP1 induces G1/S and G2/M block in the cell cycle, TCIP1 (10 nM) represses MYC and its targets while activating pro-apoptotic genes in KARPAS422 cells. TCIP1 kills diffuse large B cell lymphoma cell lines, including chemotherapy-resistant, TP53-mutant lines, at EC50 of 1-10 nM in 72 h and exhibits cell-specific and tissue-specific effects, capturing the combinatorial specificity inherent to transcription.

Lipid 16 is an ionizable lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads. Lipid 16 as a potent cell type-specific ionizable lipid for the CD11bhi macrophage population without an additional targeting moiety.

Lipid 23 is an ionizable cationic amino lipid (pKa = 5.7) that has been used with other lipids in the formulation of lipid nanoparticles (LNPs). Intravenous administration of LNPs containing lipid 23 and encapsulating an mRNA reporter accumulate specifically in the mouse liver.

SMD-3040 is a potent and selective SMARCA2 degrader with DC50 of 12 nM and demonstrates an excellent degradation selectivity for SMARCA2 over SMARCA4. SMD-3040 achieves strong tumor growth inhibition in two SMARCA4-deficient xenograft models at well-tolerated dose schedules.

OC2-K3-E10 is an ionizable cationic lipid (pKa = 6.8).1 It has been used in the formation of lipid nanoparticles (LNPs) for the delivery of CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA for genome editing in transgenic mice.

CL4F8-6 is an ionizable cationic lipid (pKa = 6.14) that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs).1 Intravenous administration of LNPs containing CL4F8-6 and encapsulating an mRNA reporter accumulate specifically in the mouse liver. LNPs containing CL4F8-6 and encapsulating mRNA encoding the Cas9 nuclease (mCas9) and single-guide RNA (sgRNA) targeting Ttr (sgTtr), the gene encoding transthyretin, have been used to induce CRISPR-mediated gene knockdown in mice resulting in a reduction of serum levels of TTR.

AOH1996 is a proliferating cell nuclear antigen (PCNA) inhibitor. AOH1996 enhances PCNA and RPB1 interaction and interferes with TRC resolution and induces DNA double-stranded breaks in a transcription dependent manner. AOH1996 almost completely inhibits the growth of xenograft tumors without causing any discernible toxicity to experimental animals.AOH1996 has superior metabolic stability as compared to the AOH1160 parent molecule. 

1O14 is an ionizable cationic lipid that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs).1 1O14-containing LNPs have been used for the delivery of IL-1β siRNA to induce gene silencing and hepatoprotective effects in a mouse model of acute liver injury induced by LPS and galactosamine (GalN).

Lipid catechol is a lipid that contains an α-aminophosphonate group, two 14-carbon acyl chains, and a catechol ring that forms a covalent bond with boronic acid-containing compounds to form lipid prodrug nanoassemblies (LPNA).1 LPNAs composed of lipid catechol conjugated to phenylboronic acid-modified ciprofloxacin (CIP-PBA) inhibit the formation of, and disrupt preformed, S. aureus biofilms and eradicate staphylococci in a mouse model of peritoneal S. aureus infection. LPNAs composed of lipid catechol conjugated to bortezomib (BTZ) reduce tumor growth and increase survival in a 4T1 murine mammary carcinoma model.

ALC-0366 (III-45) is an ionizable cationic lipid (pKa = 6.25).It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA in vivo.1,2,3 LNPs containing lipid III-45 and encapsulating a luciferase mRNA reporter accumulate in liver and adipose tissue in mice.LNPs containing lipid III-45 have been used to deliver an mRNA sequence encoding an antibody targeting the tumor-associated antigen and tight junction integral protein claudin-18 isoform 2 (claudin-18.2) to mice and reduce tumor volume in an MDA-MB-231 mouse xenograft model.

SC9 is an uncompetitive inhibitor of WT dynamin-related protein 1 (Drp1) with IC50 of 270 nM. SC9 completely prevents the LPS-induced decline in cells with fused mitochondria.

SM-102 N-oxide is potential impurity in commercial preparations of SM-102.

DIM7S is a sugar-alcohol-derived ionizable lipid with mannitol as the precursor. DIM7S LNP is 10-fold, 30-fold, 20-fold, 4-fold and 3-fold superior in mRNA delivery than Lipo 3K, Electro, ALC-0315, MC3 and SM-102, respectively. DIM7S LNP enables effective CD40 mRNA delivery into human peripheral blood monocyte-derived DCs without obvious cytotoxicity.

Recilisib (ON01210, EX-RAD) is a radioprotectant that activates the activity of AKT and PI3K in cells. It has been studied as prophylactic (use prior to radiation exposure) and therapeutic (after exposure to radiation) drug.

way-119064 is a highly potent GSK-3β inhibitor with an IC50 value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease[1].

SC-1 (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea, STAT3-IN-7), a Sorafenib analogue and potently inhibits the phosphorylation of STAT3, induces cell apoptosis through SHP-1 dependent STAT3 inactivation.

Stafia-1 is the first STAT5a inhibitor that inhibits STAT5a (IC50=22.2 μM, Ki=10.9 μM) with at least 9‐fold selectivity over STAT5b and higher selectivity against other STAT family members.

ATR inhibitor 1 is a ATR inhibitor extracted from patent WO2015187451A1, compound I-l, has a Ki value below 1 µΜ[1].

5-Chloro-2'-deoxyuridine, a thymine analog, is to study the potential of hypochlorous acid damage to DNA and DNA precursors.

Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

ATM Inhibitor-5 [formula (1)] is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1)[1].

Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively[1]. Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases[2].

Oleoyl-L-alpha-lysophosphatidic acid sodium salt is an essential metabolite for membrane biosynthesis. LPA interacts with the G protein-coupled receptors (GPCRs), called the LPA receptor and mediates signaling. It acts as a endogenous agonist for LPA1 and LPA2 receptors.